Human Genome Sciences Inc. reported a larger second-quarter loss on Thursday as it recorded higher expenses related to its lupus drug Benlysta and lower revenue compared to the year-ago period when it received payments related to an agreement with Novartis AG.
Popular Posts:
- Analyst gauges financial loss from Novartis recall
- Dendreon takes bigger 3Q loss, Provenge sales rise
- Transplant recipient struggles amid brother’s loss
- Flamel Technologies 2Q loss narrows
- Rite Aid 3Q loss narrows but revenue slips